Palisade Bio (PALI)
NASDAQ:PALI
Want to see PALI full AI Analyst Report?
PALI Stock Chart & Stats
$2.34
-$0.36(-15.79%)
At close: 4:00 PM EST
$2.34
-$0.36(-15.79%)
Day’s Range― - ―
52-Week Range$0.53 - $2.64
Previous CloseN/A
Volume307.14K
Average Volume (3M)4.53M
Market Cap
$388.17M
Enterprise Value$253.20M
Total Cash (Recent Filing)$133.38M
Total Debt (Recent Filing)$71.00K
Price to Earnings (P/E)―
Beta-0.38
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding165,884,810
10 Day Avg. Volume4,196,076
30 Day Avg. Volume4,525,639
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-12.06
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-253.20K
Enterprise Value/Ebitda-14.02
Forecast
1Y Price Target
$10.67Price Target Upside355.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EvidenceEarly clinical data showed clinical responses, symptom remission, and consistent improvements across symptoms, biomarkers, endoscopy, and tissue markers, supporting a credible biological effect for the therapy.
Commercial Opportunity And Development FundingExpansion from a niche fibrostenotic indication into broader Crohn's disease and reported cash resources sufficient to advance pivotal trials create a meaningful commercial runway if clinical benefits are confirmed.
Oral Gut-targeted Design And TolerabilityAn oral, gut‑targeted prodrug design delivers active therapy directly to the colon while limiting systemic exposure, which could provide a better-tolerated alternative to injected treatments and allow dosing flexibility.
Bears Say
Limited Treatment Exposure And GeneralizabilityShort treatment duration in early cohorts leaves uncertainty about the durability of response and how observed benefits will translate to broader luminal Crohn's populations.
Microbiome-dependent Activation RiskReliance on bacterial activation in the lower gut creates the risk that inflammation or changes in the microbiome could unpredictably alter drug activation, systemic exposure, and tolerability.
Small Trial Size And Study DesignVery small, open‑label early trials limit confidence in the findings and increase the risk that observed benefits will not replicate in larger, placebo‑controlled studies.
Palisade Bio News
PALI FAQ
What was Palisade Bio’s price range in the past 12 months?
Palisade Bio lowest stock price was $0.53 and its highest was $2.64 in the past 12 months.
What is Palisade Bio’s market cap?
Palisade Bio’s market cap is $388.17M.
When is Palisade Bio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Palisade Bio’s earnings last quarter?
Currently, no data Available
Is Palisade Bio overvalued?
According to Wall Street analysts Palisade Bio’s price is currently Undervalued.
Does Palisade Bio pay dividends?
Palisade Bio does not currently pay dividends.
What is Palisade Bio’s EPS estimate?
Palisade Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Palisade Bio have?
Palisade Bio has 165,884,810 shares outstanding.
What happened to Palisade Bio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Palisade Bio?
Currently, no hedge funds are holding shares in PALI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Palisade Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.67 (355.84% Upside)
$10.67 (355.84% Upside)
Blogger Sentiment
Bullish
PALI Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $8.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 18.8%
Last 30 Days ▲ 18.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.46%
12-Months-Change
Fundamentals
Return on Equity
-228.64%
Trailing 12-Months
Asset Growth
-25.31%
Trailing 12-Months
Company Description
Palisade Bio
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
PALI Stock 12 Month Forecast
Average Price Target
$10.67
▲(355.84% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Eledon Pharmaceuticals
―
―
Orchestra BioMed Holdings
―
Pyxis Oncology
―
Ownership Overview
0.04% Insiders
3.00% Mutual Funds
54.66% Other Institutional Investors
41.13% Public Companies and Individual Investors
Options Prices
Currently, No data available
---